Kodiak Sciences Inc (KOD) News

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio...

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results PR Newswire PALO ALTO, Calif., March...

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 PR...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and...

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire PALO ALTO, Calif., Jan. 4, 2024 PALO ALTO, Calif...

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire PALO ALTO, Calif., Nov. 21, 2023 PALO ALTO, Calif...

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif., Nov. 14, 2023 PALO...

Form 8-K - Current report

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following...

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC...

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society PR Newswire PALO ALTO, Calif., Oct...

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference PR Newswire PALO ALTO, Calif., Sept. 8, 2023 PALO ALTO...

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy...

Form 8-K - Current report